Substituted benzylaminoalkylindoles with preference for the σ2 binding site

European Journal of Medicinal Chemistry

Volumn 43, Issue 10, 2008, Pages 2073-2081

  Mamolo, Maria Grazia ^a   Zampieri, Daniele ^a   Zanette, Caterina ^a   Florio, Chiara ^a   Collina, Simona ^b   Urbano, Mariangela ^b   Azzolina, Ornella ^b   Vio, Luciano ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Receptors; Benzylaminoalkyl indole derivatives; Radioligand binding assays

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; AMINE; BENZYLAMINE DERIVATIVE; INDOLE DERIVATIVE; N BENZYL 3 [1 (4 FLUOROPHENYL) 1H INDOL 3 YL] N METHYLPROPAN 1 AMINE DERIVATIVE; N BENZYL 4 [1 (4 FLUOROPHENYL) 1H INDOL 3 YL] N METHYLBUTAN 1 AMINE DERIVATIVE; OPIATE RECEPTOR; OPIATE RECEPTOR AFFECTING AGENT; OPIATE RECEPTOR RHO1; OPIATE RECEPTOR RHO2; PENTAZOCINE; PHENYL GROUP; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; NONHUMAN; RADIOASSAY; RAT; RECEPTOR AFFINITY;

ANIMALS; BENZENE; BINDING SITES; INDOLES; PROTEIN BINDING; RATS; RECEPTORS, SIGMA; SUBSTRATE SPECIFICITY;

EID: 53149142527     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2007.09.012     Document Type: Article

References (37)

1. Martin W.R., Eades C.E., Thompson J.A., and Huppler R.E. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
2. Bowen W.D. Pharm. Acta Helv. 74 (2000) 211-218
3. Hanner M., Moebius F.F., Flandorfer A., Knaus H.G., Striessnig J., Kempner E., and Glossmann H. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8072-8077
4. Kekuda R., Prasad P.D., Fei Y., Leibach F.H., and Ganapathy V. Biochem. Biophys. Res. Commun. 229 (1996) 553-558
5. Glennon R.A., Ablordeppey S.Y., Ismaiel A.M., El-Ashmawy M.B., Fischer J.B., and Howie B.K. J. Med. Chem. 37 (1994) 1214-1219
6. Ablordeppey S.Y., Fischer J.B., Law H., and Glennon R.A. Bioorg. Med. Chem. 10 (2002) 2759-2765
7. Glennon R.A. Mini Rev. Med. Chem. 5 (2005) 927-940
8. Gund T.M., Floyd J., and Jung D. J. Mol. Graphics Modell. 22 (2004) 221-230
9. Mach R.H., Smith C.R., and Childers S.R. Life Sci. 57 (1995) 57-62
10. Bowen W.D., Bertha C.M., Vilner B.J., and Rice K.C. Eur. J. Pharmacol. 278 (1995) 257-260
11. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., and Taylor D.P. Trends Pharmacol. Sci. 13 (1992) 85-86
12. Mach R.B., Huang Y., Freeman R.A., Wu L., Vangveravong S., and Luedtke R.R. Bioorg. Med. Chem. Lett. 14 (2004) 195-202
13. Wyrick S.D., and Booth R.C. Drugs Future 20 (1995) 1033-1044
14. Debonnel G., and De Montigny C. Life Sci. 58 (1996) 721-734
15. Monnet F.P., Debonnel G., and De Montigny C. J. Pharmacol. Exp. Ther. 261 (1992) 123-130
16. Maurice T., and Lockhart B.P. Prog. Neuropsychopharmacol. Biol. Psychiatry 21 (1997) 69-102
17. King M., Pan Y.X., Mei J., Chang A., Xu J., and Pasternak G.W. Eur. J. Pharmacol. 331 (1997) R5-R6
18. McCracken K.A., Bowen W.D., Walker F.O., De Costa B., and Matsumoto R.R. Eur. J. Pharmacol. 370 (1999) 225-232
19. Modell S., Nober D., and Holzbach R. Pharmacopsychiatry 29 (1996) 63
20. Huber M.T., Gotthardt U., Schreiber W., and Krieg J.C. Pharmacopsychiatry 32 (1999) 68
21. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., and Rice K.C. Pharmacol. Rev. 42 (1990) 355-402
22. Bastianetto S., Perrault G., and Ranger D.J. Neuropharmacology 34 (1995) 107-114
23. Jeanjean A.P., Laterre E.C., and Maloteaux J.M. Biol. Psychiatry 41 (1997) 1010-1019
24. Vilner B.J., John C.S., and Bowen W.D. Cancer Res. 55 (1995) 408-413
25. Crawford K.W., and Bowen W.D. Cancer Res. 62 (2002) 313-322
26. Vilner B.J., and Bowen W.D. J. Pharmacol. Exp. Ther. 292 (2000) 900-911
27. Crawford K.W., Coop K.W., and Bowen W.D. Eur. J. Pharmacol. 443 (2002) 207-209
28. Caveliers V., Everaert H., Lahoutte T., Dierickx L.O., John C.S., and Bossuyt A. Eur. J. Nucl. Med. 28 (2001) 133-135
29. Friebe M., Mahmood A., Bolzati C., Drews A., Johannsen B., Eisenhut M., Kraemer M., Davison A., and Jones A.G. J. Med. Chem. 44 (2001) 3132-3140
30. Choi S.R., Yang B., Plo{combining double acute accent}ssl K., Chumpradit S., Wey S.P., Acton P.D., Wheeler K., Mach R.H., and Kung H.F. Nucl. Med. Biol. 28 (2001) 657-666
31. Perregaard J., Molzen E.K., Meier E., and Sánchez C. J. Med. Chem. 38 (1995) 1998-2008
32. Molzen E.K., Perregaard J., and Meier E. J. Med. Chem. 38 (1995) 2009-2017
33. Benghiat E., and Crooks P.A. J. Med. Chem. 26 (1983) 1470-1477
34. Berardi F., Ferorelli S., Abate C., Colabufo N.A., Contino M., Perrone R., and Tortorella V. J. Med. Chem. 47 (2004) 2308-2317
35. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., and De Costa B. Eur. J. Pharmacol. 280 (1995) 301-310
36. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., and Bowen W.D. Eur. J. Pharmacol. 268 (1994) 9-18
37. Torrence-Campbell C., and Bowen W.D. Eur. J. Pharmacol. 304 (1996) 201-210